Gastrointestinal · PANCE / PANRE

Hepatocellular Carcinoma (HCC)

Written & clinically reviewed by Ryan Busch, PA-C · Updated August 2026 · Report an error

Primary liver cancer in cirrhosis or chronic HBV; surveillance improves outcomes; many curative options.

Also known as: HCC, hepatocellular carcinoma, hepatoma, liver cancer

Overview

Primary malignancy of hepatocytes, accounting for >90% of primary liver cancers. Typically arises in cirrhotic livers but can occur in non-cirrhotic chronic HBV.

Epidemiology

~42,000 new cases and ~30,000 deaths annually in the US; rising incidence (HCV cohort, alcohol, MASLD). 5-year survival ~20% overall; >70% if detected at very early stage. Worldwide, leading cancer in some Asian/African countries due to endemic HBV.

Try two board-style Hepatocellular Carcinoma questions

Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.

Question 1GastrointestinalMedium
A 50-year-old male with non-alcoholic fatty liver disease (NAFLD) cirrhosis has a 2.2 cm arterially enhancing liver lesion with washout on portal venous phase MRI. Alpha-fetoprotein (AFP) is 120 ng/mL. There is no vascular invasion. Model for End-Stage Liver Disease (MELD) is 12. Which of the following is the most likely diagnosis?
  • AHepatocellular carcinoma
  • BHepatic adenoma
  • CFocal nodular hyperplasia
  • DMetastatic colorectal cancer
Reveal answer & full explanation
Correct answer: A — Hepatocellular carcinoma
  • AHepatocellular carcinoma✓
  • BHepatic adenoma
  • CFocal nodular hyperplasia
  • DMetastatic colorectal cancer

Why hepatocellular carcinoma is correct

  • Arterial hyperenhancement plus washout on multiphase MRI in a cirrhotic liver meets Liver Imaging Reporting and Data System (LI-RADS) LR-5 criteria for hepatocellular carcinoma (HCC); biopsy is not required.
  • The 2.2 cm lesion size with preserved liver function (MELD 12) meets Milan criteria, making the patient a candidate for curative therapy: radiofrequency ablation (RFA), resection, or transplant evaluation.

Why the others are wrong

  • D) Metastatic colorectal cancer — Metastases typically show rim enhancement without washout on multiphase imaging.
  • C) Focal nodular hyperplasia — Focal nodular hyperplasia (FNH) shows arterial enhancement with delayed retention (not washout).
  • B) Hepatic adenoma — Adenomas are uncommon in the setting of cirrhosis.
Question 2GastrointestinalEasy
A 55-year-old man with chronic hepatitis C cirrhosis undergoes surveillance ultrasound every 6 months. A new 1.5 cm liver lesion is found. AFP is 280 ng/mL. CT shows arterial enhancement with washout in the portal venous phase. What is the most appropriate next step?
  • ARepeat ultrasound surveillance in 3 months
  • BReferral for treatment planning based on imaging diagnosis
  • CMRI of the liver
  • DLiver biopsy to confirm hepatocellular carcinoma (HCC)
Reveal answer & full explanation
Correct answer: B — Referral for treatment planning based on imaging diagnosis
  • ARepeat ultrasound surveillance in 3 months
  • BReferral for treatment planning based on imaging diagnosis✓
  • CMRI of the liver
  • DLiver biopsy to confirm hepatocellular carcinoma (HCC)

Why Referral for treatment planning based on imaging diagnosis is correct

  • Hepatocellular carcinoma (HCC) in cirrhosis can be diagnosed non-invasively by Liver Imaging Reporting and Data System (LI-RADS) criteria for lesions 1 cm or larger demonstrating arterial hyperenhancement with portal venous washout on dynamic CT or MRI
  • Biopsy is not required when imaging is classic
  • AFP above 200 ng/mL in cirrhosis with a liver mass is strongly supportive of HCC
  • Lesions meeting these criteria should proceed directly to treatment planning (resection, ablation, or transplant candidacy) per Barcelona Clinic Liver Cancer (BCLC) staging

Why the others are wrong

  • A) Repeat ultrasound surveillance in 3 months — a 1.5 cm lesion with classic HCC imaging features requires treatment, not surveillance delay
  • C) MRI of the liver — MRI is an equivalent modality to CT for LI-RADS diagnosis, but CT has already demonstrated classic arterial enhancement with washout; repeating imaging with MRI is unnecessary when the diagnosis is already established by CT
  • D) Liver biopsy to confirm hepatocellular carcinoma (HCC) — biopsy is reserved for indeterminate lesions; classic imaging criteria in a cirrhotic patient are sufficient for diagnosis without tissue confirmation
🔒 Free preview limit reached

Keep reading — start your free trial

You've read your 2 free diagnosis previews. Create your free account to unlock the full Hepatocellular Carcinoma (HCC) outline — plus all 514 diagnoses, 6,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.

Start your 7-day free trial → Sign in
Free to start · No credit card · Cancel anytime

Risk factors

  • Cirrhosis of any etiology — most important risk factor
  • Chronic HBV — can cause HCC WITHOUT cirrhosis (integration of HBV DNA into host genome)
  • Chronic HCV (largely mitigated by DAA SVR but persists in cirrhotic patients)
  • MASH/MASLD with cirrhosis (rising etiology)
  • Alcohol-associated cirrhosis
  • Hemochromatosis with cirrhosis
  • Aflatoxin exposure (Aspergillus contamination of stored grains/nuts — sub-Saharan Africa, parts of Asia)
  • Alpha-1 antitrypsin deficiency, Wilson disease, autoimmune hepatitis (with cirrhosis)
  • Tobacco, diabetes, obesity (independent contributors)
  • Family history; Asian male >40, Asian female >50, African origin >20 (start surveillance earlier)

Pathophysiology

Chronic inflammation, oxidative stress, and regenerative hepatocyte turnover drive accumulation of genetic mutations (TERT promoter, TP53, CTNNB1, AXIN1). HBV DNA integration directly disrupts tumor suppressor genes and induces malignant transformation even in non-cirrhotic livers. HCC is highly vascular and characteristically derives blood supply from the hepatic artery (vs portal vein for normal liver).

Clinical presentation

Symptoms

  • Often ASYMPTOMATIC in early stage — detected on surveillance
  • RUQ pain or fullness
  • Weight loss, anorexia, fatigue
  • Worsening hepatic decompensation (new/worsening ascites, encephalopathy, jaundice) in a previously stable cirrhotic
  • Paraneoplastic syndromes: erythrocytosis (EPO), hypoglycemia (IGF-2), hypercalcemia (PTHrP), watery diarrhea
  • Acute hemoperitoneum from tumor rupture (rare but life-threatening)

Signs / physical exam

  • Hepatomegaly, palpable liver mass
  • Bruit over liver (highly vascular)
  • Stigmata of cirrhosis
  • Worsening ascites, encephalopathy, jaundice
  • Signs of metastatic disease (lung, bone, lymph nodes, adrenal)

Classic findings

New worsening of stable compensated cirrhosis — always evaluate for HCC.

Differential diagnosis

  • Cirrhotic regenerative nodule / dysplastic nodule — Lacks arterial enhancement with washout; LI-RADS classification
  • Intrahepatic cholangiocarcinoma — Peripheral, mass-forming or periductal; delayed/persistent enhancement vs HCC washout; biopsy
  • Hepatic hemangioma — Most common benign liver mass; peripheral nodular enhancement with centripetal fill-in on MRI
  • Focal nodular hyperplasia (FNH) — Central scar, hyperintense on hepatobiliary phase MRI with hepatocyte-specific contrast
  • Hepatocellular adenoma — Premenopausal women with OCP/anabolic steroid use; resect if >5 cm or beta-catenin mutated due to bleeding/malignancy risk
  • Metastasis (colon, breast, lung, melanoma) — Multiple lesions, no underlying cirrhosis, primary tumor history
  • Liver abscess — Fever, leukocytosis, fluid collection; risk factors (cholangitis, diverticulitis); aspiration culture

Diagnostic workup

Diagnostic criteria

LI-RADS (Liver Imaging Reporting and Data System) in cirrhotic patients: LR-5 (definite HCC) — arterial hyperenhancement + washout + capsule or threshold growth. Biopsy not required for LR-5 in cirrhosis. AASLD criteria similar.

Labs

  • Alpha-fetoprotein (AFP) — elevated in ~70% of HCC but not specific; ≥400 ng/mL with characteristic imaging supports diagnosis
  • PIVKA-II (DCP) — adjunct biomarker (not widely used in US)
  • LFTs, INR, albumin (Child-Pugh, MELD)
  • CBC (thrombocytopenia from hypersplenism; erythrocytosis from paraneoplastic EPO)
  • Hepatitis B and C serologies
  • Iron studies, ceruloplasmin, A1AT (etiologic workup if not established)

Imaging

  • Multiphasic CT or MRI with IV contrast — diagnostic; arterial phase hyperenhancement + portal venous or delayed phase washout (LR-5 by LI-RADS) is sufficient for diagnosis in cirrhotic patient WITHOUT biopsy
  • Liver biopsy — reserve for lesions with indeterminate imaging or in non-cirrhotic livers
  • Surveillance: abdominal ultrasound ± AFP every 6 months in cirrhotic patients and high-risk HBV carriers
  • Staging: CT chest/abdomen/pelvis; bone scan if symptoms; PET-CT not routinely used
  • Hepatobiliary contrast MRI (gadoxetate disodium) — useful for indeterminate small lesions

Diagnostic algorithm

BCLC StageTumor StatusLiver Function / PSTreatment
0 (Very early)Single ≤2 cmChild-Pugh A, PS 0Resection or ablation
A (Early)Single any size or ≤3 nodules ≤3 cmChild-Pugh A-B, PS 0Resection, transplant (if Milan), or ablation
B (Intermediate)MultinodularChild-Pugh A-B, PS 0TACE or TARE; consider downstaging
C (Advanced)Vascular invasion or extrahepatic spreadChild-Pugh A, PS 1-2Systemic therapy (atezolizumab + bevacizumab)
D (Terminal)AnyChild-Pugh C or PS ≥3Best supportive care
Barcelona Clinic Liver Cancer (BCLC) staging and treatment algorithm for HCC.

Treatment

First-line

  • Stage- and liver-function-directed therapy (BCLC algorithm)
  • Multidisciplinary tumor board
  • Treat underlying liver disease (HBV antivirals, HCV DAAs, alcohol cessation, MASH management)

Very early / early (BCLC 0/A) — single tumor ≤2 cm or up to 3 tumors ≤3 cm; preserved liver function

  • Surgical resection (Child-Pugh A, no portal hypertension)
  • Liver transplantation — best for those within Milan criteria (single ≤5 cm OR up to 3 lesions each ≤3 cm)
  • Local ablation (radiofrequency or microwave ablation) — curative for small tumors when resection contraindicated

Intermediate (BCLC B) — multinodular, no vascular invasion or metastases

  • Transarterial chemoembolization (TACE) or transarterial radioembolization (TARE/Y-90)
  • Consider downstaging to transplant criteria

Advanced (BCLC C) — vascular invasion or extrahepatic spread, preserved liver function

  • First-line systemic: atezolizumab + bevacizumab (IMbrave150) — for Child-Pugh A only; EGD to exclude varices first
  • Alternative first-line: tremelimumab + durvalumab (HIMALAYA), lenvatinib, sorafenib (historical)
  • Second-line: cabozantinib, regorafenib, ramucirumab (if AFP ≥400), nivolumab + ipilimumab

Terminal (BCLC D) — poor performance status or end-stage liver function

  • Best supportive care, palliative care, hospice as appropriate

Complications

  • Tumor rupture with hemoperitoneum
  • Portal vein tumor thrombosis (poor prognostic factor)
  • Worsening hepatic decompensation
  • Paraneoplastic syndromes
  • Metastases — lung, bone, lymph nodes, adrenal
  • Liver failure as a competing risk for mortality
  • Treatment toxicity: post-TACE syndrome (fever, pain, transaminitis), Y-90 lung shunting, immune-related adverse events with checkpoint inhibitors, hemorrhage with bevacizumab

PANCE pearls

  • Surveillance with ultrasound ± AFP every 6 months is recommended in ALL cirrhotic patients (regardless of etiology or compensation) and high-risk HBV carriers — improves survival.
  • HBV is the only chronic hepatitis where HCC develops in non-cirrhotic livers — surveillance recommended in Asian male >40, Asian female >50, African origin >20, family history of HCC, all cirrhotic HBV.
  • Cure of HCV with DAAs reduces but does NOT eliminate HCC risk in cirrhotic patients — continue surveillance.
  • LR-5 imaging criteria (arterial hyperenhancement + washout) in a cirrhotic patient is diagnostic for HCC — BIOPSY NOT REQUIRED.
  • Milan criteria for liver transplant: single tumor ≤5 cm OR up to 3 tumors each ≤3 cm, no vascular invasion or extrahepatic spread.
  • Atezolizumab + bevacizumab (IMbrave150) is preferred first-line systemic therapy for advanced HCC over sorafenib — EGD to exclude varices first (bevacizumab bleeding risk).
  • Sorafenib was the first systemic agent (SHARP trial 2008) — now relegated to later lines.
  • Post-TACE: monitor for post-embolization syndrome (fever, RUQ pain, transaminitis) — supportive care.
  • Paraneoplastic erythrocytosis (EPO production) is a classic HCC association.
  • Fibrolamellar HCC — variant in young patients WITHOUT cirrhosis; better prognosis; surgical resection mainstay.

References

  • AASLD 2023 — Singal AG et al. AASLD Practice Guidance on Prevention, Diagnosis, and Treatment of Hepatocellular Carcinoma. Hepatology 2023;78:1922-1965
  • IMbrave150 — Finn RS et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. NEJM 2020;382:1894-1905
  • SHARP Trial — Llovet JM et al. Sorafenib in Advanced Hepatocellular Carcinoma. NEJM 2008;359:378-390
  • Milan Criteria — Mazzaferro V et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. NEJM 1996;334:693-699

Practice Gastrointestinal questions on FirstPassPA

Turn this outline into retention. 6,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.

Answer the 2 free questions above → Get today's free question →

Related Gastrointestinal diagnoses

Gastroesophageal Reflux Disease (GERD)Peptic Ulcer Disease (PUD)Helicobacter pylori InfectionEosinophilic Esophagitis (EoE)Esophageal VaricesAchalasiaEsophageal CancerGastric CancerIrritable Bowel Syndrome (IBS)Crohn DiseaseUlcerative Colitis (UC)Diverticulitis and DiverticulosisColorectal Cancer (CRC)Hemorrhoids

Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.